Abner Herrman & Brock LLC Has $23.48 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Abner Herrman & Brock LLC boosted its stake in Eli Lilly and Company (NYSE:LLY) by 0.4% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 26,508 shares of the company’s stock after buying an additional 103 shares during the period. Eli Lilly and Company makes up 2.8% of Abner Herrman & Brock LLC’s portfolio, making the stock its 11th largest holding. Abner Herrman & Brock LLC’s holdings in Eli Lilly and Company were worth $23,484,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Lynx Investment Advisory acquired a new stake in Eli Lilly and Company during the 2nd quarter worth approximately $32,000. LGT Financial Advisors LLC acquired a new stake in shares of Eli Lilly and Company during the second quarter worth $36,000. Redmont Wealth Advisors LLC bought a new stake in shares of Eli Lilly and Company in the first quarter valued at about $40,000. Morton Brown Family Wealth LLC grew its stake in shares of Eli Lilly and Company by 45.5% in the second quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock valued at $41,000 after acquiring an additional 15 shares in the last quarter. Finally, Richardson Financial Services Inc. bought a new position in Eli Lilly and Company during the fourth quarter worth about $43,000. 82.53% of the stock is owned by institutional investors.

Analysts Set New Price Targets

LLY has been the topic of a number of analyst reports. Truist Financial restated a “buy” rating and set a $1,000.00 target price (up previously from $892.00) on shares of Eli Lilly and Company in a research report on Tuesday, June 25th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $1,025.00 target price on shares of Eli Lilly and Company in a report on Thursday, October 3rd. Bank of America increased their price target on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Wells Fargo & Company upped their target price on Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Friday, August 9th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $885.00 price objective on shares of Eli Lilly and Company in a report on Monday, September 16th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $977.35.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $919.91 on Thursday. The stock has a market capitalization of $874.29 billion, a price-to-earnings ratio of 135.48, a PEG ratio of 2.78 and a beta of 0.42. Eli Lilly and Company has a 52-week low of $547.61 and a 52-week high of $972.53. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. The stock’s 50 day moving average price is $904.41 and its two-hundred day moving average price is $850.31.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The business had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. On average, equities analysts predict that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.